Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC). The life quality and survival of this subgroup of patients were constantly improving owing to the continuous iteration and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yufeng, Mao, Tianyu, Wang, Jing, Zheng, Hongrui, Hu, Ziyi, Cao, Pingping, Yang, Suisui, Zhu, Lingyun, Guo, Shunyao, Zhao, Xinfei, Tian, Yue, Shen, Hua, Lin, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088170/
https://www.ncbi.nlm.nih.gov/pubmed/37041601
http://dx.doi.org/10.1186/s12964-023-01082-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088170/
https://www.ncbi.nlm.nih.gov/pubmed/37041601
http://dx.doi.org/10.1186/s12964-023-01082-8

Ejemplares similares